Full-Time

Business Development Manager

Deadline 4/14/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Boston, MA, USA + 2 more

More locations: Washington, DC, USA | Philadelphia, PA, USA

Remote

Category
Business & Strategy (1)
Required Skills
Sales
Lead Generation
Salesforce
Requirements
  • Bachelor’s degree in a science-related field.
  • An MBA or a Master’s/PhD in a scientific discipline is highly advantageous.
  • Minimum of 5 years of experience in sales or business development, preferably within scientific, biotechnology, or advanced technology sectors.
  • Proven ability to assess customer needs and translate them into effective sales and marketing strategies that support business growth.
  • Proficiency with Salesforce CRM and business analytics tools for managing pipelines, forecasting, and account planning, as well as Microsoft Office suite.
  • Travel up to 50% of the time.
Responsibilities
  • Identify and pursue new business opportunities, partnerships, and collaborations within DMPK.
  • Generate and qualify leads through networking, cold outreach, industry events, and digital channels.
  • Develop and execute strategies to drive DMPK sales growth across the U.S.
  • Maintain an accurate, up-to-date sales pipeline and provide reliable sales forecasting for the region.
  • Collaborate with regional sales and marketing teams to convert DMPK opportunities into orders.
  • Support the sales process through customer presentations, product demonstrations, and contract negotiations.
  • Develop and implement tactical sales plans with regional teams to ensure DMPK meets or exceeds Annual Operating Plan targets.
  • Set sales goals and create actionable plans to achieve them.
  • Design and deliver remote training programs for sales and marketing teams on DMPK workflows, applications, and sales strategies.
  • Ensure teams are equipped with the tools, content, and knowledge required for effective selling.
  • Partner with regional stakeholders to deploy virtual tools, campaigns, and initiatives that increase product awareness and build the DMPK sales funnel.
  • Develop and execute promotional programs to accelerate lead generation and sales conversion.
  • Build and maintain strong, long-term relationships with DMPK prospects and customers.
  • Capture customer feedback, success stories, and unmet needs to inform commercial strategy.
  • Ensure exceptional customer service and drive customer satisfaction and repeat business.
  • Provide regular reports on sales performance, market dynamics, and customer insights to the Pharma Program lead.
  • Use data-driven insights to refine strategies and enhance commercial effectiveness.
  • Maintain a deep understanding of Quantitative/ Qualitative LC-MS and Flow cytometry bioanalysis and related technologies to clearly articulate scientific and commercial value to internal teams and external customers.
  • Gather and communicate feedback from customers, field sales, and marketing to support continuous improvement of DMPK bioanalytical solutions.
  • Work closely with regional sales and marketing teams, product managers, and the broader Analytical Sciences Division / LCMS business segment to deliver comprehensive and integrated DMPK bioanalytical solutions to customers.
Desired Qualifications
  • Knowledge/experience of flow cytometry advantageous.
  • Hands-on experience of LC-MS/MS bioanalysis and work in a regulated pharma environment.
  • MBA or Master’s/PhD in a scientific discipline is highly advantageous.

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
  • Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
  • China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.

What critics are saying

  • Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
  • $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
  • BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.

What makes Waters Corporation unique

  • BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
  • omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
  • ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Waters Corporation who can refer or advise you

Benefits

Hybrid Work Options

Company News

PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.